Vertex and crispr therapeutics announce acceptance of late-breaking abstract for ctx001™ at the 2022 annual european hematology association (eha) congress

Boston & zug, switzerland & cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced new late-breaking clinical data accepted for oral presentation at the 2022 european hematology association (eha) congress. vertex also announced three abstracts accepted for poster presentation at eha. late-breaking abstract #lb2367 entitled “efficacy and safety of a single dose of ctx001 for transfusion-dependent Βeta-thalassem
VRTX Ratings Summary
VRTX Quant Ranking